Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24978426 | 0.96 | HSD17B10 (0.51) | HSD17B10KDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL24978418 | 0.85 | HDAC3 (0.46) | HSD17B10KDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL24978425 | 0.81 | HSD17B10 (0.47) | HSD17B10KDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL24978408 | 0.81 | KMT2A (0.46) | KMT2ATSHRSMN1; SMN2RAB9AHDAC3 | |
| SCHEMBL23331000 | 0.78 | MEN1 (0.43) | KMT2ATSHRALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL23301458 | 0.78 | ABL1 (0.45) | KMT2AHPGDSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL23331087 | 0.77 | HDAC1 (0.47) | KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL23330648 | 0.76 | HDAC3 (0.46) | KDM4EKMT2ATSHRSMN1; SMN2RAB9A | |
| SCHEMBL24978673 | 0.75 | PIP5K1C (0.41) | HDAC3HDAC1HDAC2 | |
| SCHEMBL17111799 | 0.69 | NFKB1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | HSD17B10 332/4885KDM4E 2018/4885KMT2A 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.